Evidence supporting the use of: Saccharomyces boullardii
For the health condition: Crohn's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Saccharomyces boulardii is a probiotic yeast with some scientific evidence supporting its use in gastrointestinal disorders, including Crohn’s Disease (CD). A few randomized controlled trials and systematic reviews have investigated its efficacy, but the results are mixed and overall evidence remains limited. Some studies suggest that S. boulardii, when used as an adjunct to standard therapies (such as mesalazine), may help maintain remission or reduce the frequency of relapse in patients with Crohn's Disease. For example, a small, double-blind, placebo-controlled trial published in 2000 (Guslandi et al.) found that S. boulardii reduced relapse rates over a 6-month period. However, other studies and meta-analyses note that the data are insufficient to draw strong conclusions, and several trials have found no significant benefit.

The proposed mechanism of action involves modulation of the gut microbiota, enhancement of intestinal barrier function, and anti-inflammatory effects. Nevertheless, major gastroenterology guidelines (such as those from the American Gastroenterological Association) do not currently recommend S. boulardii as a standard treatment for Crohn's Disease, primarily due to the lack of large, well-designed trials and inconsistent results.

In summary, while there is some scientific investigation into S. boulardii for Crohn's Disease, the evidence base is weak (rated 2/5), and it is not considered a mainstream or guideline-recommended therapy for this condition.

More about Saccharomyces boullardii
More about Crohn's Disease

Products containing Saccharomyces boullardii

We currently have no products on Vitabase that contain this ingredient.